The challenges of access to innovative medicines with limited evidence in the European Union

The European Medicines Agency (EMA) fosters access to innovative medicines through accelerated procedures and flexibility in the authorization requirements for diseases with unmet medical needs, such as many rare diseases as well as oncological diseases. However, the resulting increase of medicines...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallano, Antonio, Pontes, Caridad, Agustí, Antònia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500193/
https://www.ncbi.nlm.nih.gov/pubmed/37719853
http://dx.doi.org/10.3389/fphar.2023.1215431